Horizon Therapeutics celebrated its second consecutive win in Sjögren’s syndrome after dazodalibep met its primary endpoint in the second Phase II trial patient population, the company announced Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,